Mitral regurgitation has another magic bullet bitten the dust?

Circulation: Heart Failure

Volumn 6, Issue 4, 2013, Pages 624-626

  Borer, Jeffrey S ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Disease; Editorials; Mitral valve; Pharmacological therapy; Ventricular remodeling

Indexed keywords

VASODILATOR AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; CARVEDILOL; PROPANOLAMINE DERIVATIVE;

AORTA VALVE REGURGITATION; CARDIOVASCULAR MORTALITY; CORONARY ARTERY DISEASE; HEART ARRHYTHMIA; HEART CATHETERIZATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE CONTRACTILITY; HEART RIGHT VENTRICLE PRESSURE; HEART STROKE VOLUME; HUMAN; MITRAL VALVE REGURGITATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; DISEASES; DRUG EFFECT; DRUG THERAPY; EDITORIALS; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; MITRAL VALVE; MORTALITY; NOTE; PATHOPHYSIOLOGY;

DISEASE; EDITORIALS; MITRAL VALVE; PHARMACOLOGICAL THERAPY; VENTRICULAR REMODELING;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARBAZOLES; MITRAL VALVE INSUFFICIENCY; PROPANOLAMINES; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84884725180     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.113.000409     Document Type: Review

References (20)

1. Starling MR, Kirsh MM, Montgomery DG, Gross MD. Impaired left ventricular contractile function in patients with long-term mitral regurgitation and normal ejection fraction. J Am Coll Cardiol. 1993;22:239-250.
2. Chatterjee K, Parmley WW, Swan HJ, Berman G, Forrester J, Marcus HS. Beneficial effects of vasodilator agents in severe mitral regurgitation due to dysfunction of subvalvar apparatus. Circulation. 1973;48:684-690.
3. Borer JS, Redwood DR, Itscoitz SB, Goldstein RE, Epstein SE. Nitroglycerin-induced improvement in exercise tolerance and hemodynamics in patients with chronic rheumatic valvular heart disease. Am J Cardiol. 1978;41:302-307.
4. Wisenbaugh T, Sinovich V, Dullabh A, Sareli P. Six month pilot study of captopril for mildly symptomatic, severe isolated mitral and isolated aortic regurgitation. J Heart Valve Dis. 1994;3:197-204.
5. Shon HR, Dorn R, Barthel P, Shoming J. Effect of 12 months quinapril therapy in asymptomatic patients with chronic aortic regurgitation. J Heart Valve Dis. 1994;3:500-509.
6. Sampaio RO, Grinberg M, Leite JJ, Tarasoutchi F, Chalela WA, Izaki M, Spina GS, Rossi EG, Mady C. Effect of enalapril on left ventricular diameters and exercise capacity in asymptomatic or mildly symptomatic patients with regurgitation secondary to mitral valve prolapse or rheumatic heart disease. Am J Cardiol. 2005;96:117-121.
7. Dell'italia LJ, Balcells E, Meng QC, Su X, Schultz D, Bishop SP, Machida N, Straeter-Knowlen IM, Hankes GH, Dillon R, Cartee RE, Oparil S. Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs. Am J Physiol. 1997;273(2 Pt 2):H961-H970.
8. Nemoto S, Hamawaki M, De Freitas G, Carabello BA. Differential effects of the angiotensin-converting enzyme inhibitor lisinopril versus the beta-adrenergic receptor blocker atenolol on hemodynamics and left ventricular contractile function in experimental mitral regurgitation. J Am Coll Cardiol. 2002;40:149-154.
9. Mulieri LA, Lauvitt BJ, Martin BJ, Haeberle JR, Alpert NR. Myocardial force-frequency defect in mitral regurgitation reversed by forskolin. Circulation. 1993;88:2700-2704.
10. Starling MR. Emerging biology of mitral regurgitation: implications for further therapy. Adv Cardiol. 2002;39:15-24.
11. Mehta RH, Supiano MA, Oral H, Grossman PM, Montgomery DS, Smith MJ, Starling MR. Compared with control subjects, the systemic sympathetic nervous system is activated in patients with mitral regurgitation. Am Heart J. 2003;145:1078-1085.
12. Tsutsui H, Spinale FG, Nagatsu M, Schmid PG, Ishihara K, DeFreyte G, Cooper G IV, Carabello BA. Effects of chronic beta-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. J Clin Invest. 1994;93:2639-2648.
13. Nagatsu M, Spinale FG, Koide M, Tagawa H, DeFreitas G, Cooper G IV, Carabello BA. Bradycardia and the role of beta-blockade in the amelioration of left ventricular dysfunction. Circulation. 2000;101:653-659.
14. Varadarajan P, Joshi N, Appel D, Duvvuri L, Pai RG. Effect of Betablocker therapy on survival in patients with severe mitral regurgitation and normal left ventricular ejection fraction. Am J Cardiol. 2008;102:611-615.
15. Pu M, Gao Z, Pu DK, Davidson Jr WR. Effects of early, late, and longterm nonselective β-blockade on left ventricular remodeling, function, and survival in chronic organic mitral regurgitation. Circ Heart Fail. 2013;6: 756-762.
16. Sabri A, Rafiq K, Seqqat R, Kolpakov MA, Dillon R, Dell'italia LJ. Sympathetic activation causes focal adhesion signaling alteration in early compensated volume overload attributable to isolated mitral regurgitation in the dog. Circ Res. 2008;102:1127-1136.
17. Stewart RA, Raffel OC, Kerr AJ, Gabriel R, Zeng I, Young AA, Cowan BR. Pilot study to assess the influence of beta-blockade on mitral regurgitant volume and left ventricular work in degenerative mitral valve disease. Circulation. 2008;118:1041-1046.
18. Ahmed MI, Aban I, Lloyd SG, Gupta H, Howard G, Inusah S, Peri K, Robinson J, Smith P, McGiffin DC, Schiros CG, Denney T Jr, Dell'Italia LJ. A randomized controlled phase IIb trial of beta(1)-receptor blockade for chronic degenerative mitral regurgitation. J Am Coll Cardiol. 2012;60:833-838.
19. Plante E, Lachance D, Champetier S, Drolet M-C. Benefits of long-term β- blockade in experimental chronic aortic regurgitation. Am J Physiol - Heart and Circulatory Physiol. 2008;294:H1888-H1895.
20. Doggrell SA, Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res. 1998;39:89-105.